Arms |
Assigned Interventions |
Experimental:Binimetinib Combine with Palbociclib Phase 1
Palbociclib will be administered orally once daily
Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle
Binimetinib will be administered orally twice daily
Patients will be dosed with Binimetinib continuously through the four weeks per cycle
|
Drug:Palbociclib It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6 |
Experimental:Binimetinib Combine with Palbociclib Phase 2
Palbociclib will be administered orally once daily
Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle
Binimetinib will be administered orally twice daily
Patients will be dosed with Binimetinib continuously through the four weeks per cycle
|
Experimental:Binimetinib Phase 2
Binimetinib will be administered orally twice daily
Patients will be dosed with Binimetinib continuously through the four weeks per cycle
|
Experimental:Palbociclib Phase 2
Palbociclib will be administered orally once daily
Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle
|